[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-iii-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-iii-breast-cancer":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,44,79,110,147,180,208,233,263,284,312],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100478622","phase-3-elacestrant-for-treating-erher2--breast-cancer-patients-with-ctdna-relapse-treat-ctdna-100478622",false,"NCT05512364","Elacestrant for Treating ER+\u002FHER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)","Elacestrant for Treating ER+\u002FHER2- Breast Cancer Patients With ctDNA Relapse","TREAT ctDNA","Inclusion Criteria:\n\n1. ctDNA screening phase:\n\n   Main inclusion criteria:\n\n   • Female (both pre- and postmenopausal) or male patients with histologically confirmed ER positive (regardless of PR),\n\n   HER2 negative breast cancer, according to local pathologist:\n   * ER-positive defined as ≥ 10% of cells staining positive for ER or Allred proportion score ≥3\n   * HER2-negative defined as a score of 0, 1+ by immunohistochemistry (IHC) or a negative in situ hybridization (ISH) based on single-probe average HER2 copy number, as per American Society of Clinical Oncology guidelines\n   * Intermediate to high risk of recurrence after definitive treatment for early breast cancer, defined as:\n\n   FOR PATIENTS TREATED WITH PRIMARY SURGERY:\n   * Any patient with ≥ 4 positive axillary lymph nodes (stage pN2-3).\n   * 1-3 positive axillary lymph nodes (stage pN1) and either:\n   * Tumour size ≥ 5 cm or\u002Fand\n   * Histologic grade 3 or\u002Fand\n   * Ki67≥20% or\u002Fand\n   * High genomic risk defined as Oncotype Dx Recurrence Score \\>=26, Mammaprint high risk, Prosigna score \\>40 or EPclin risk score \\>=4.0.\n   * Negative axillary lymph nodes (stage pN0) and tumour size ≥ 2 cm and either\n   * Histologic grade 3 a or\u002Fand\n   * Ki67≥20% and\u002For\n   * High genomic risk defined as Oncotype Dx Recurrence Score \\>=26, Mammaprint high risk, Prosigna score \\>60 or EPclin risk score \\>=4.0. FOR PATIENTS TREATED WITH NEOADJUVANT\n\n   SYSTEMIC TREATMENT FOLLOWED BY SURGERY:\n   * Patient may have received neoadjuvant endocrine therapy or neoadjuvant chemotherapy provided that:\n   * The initial tumour and\u002For the tumour after surgery meet the criteria above defined for patients treated with primary surgery or the initial tumour was staged as cT4anyN and\n   * There is no pathological complete response, defined as no invasive disease in the breast and axilla (ypT0\u002Fis ypN0).\n   * Age ≥18 years\n   * Patients must have received at least 1 year and up to 7.5 years of ET and planned to continue adjuvant ET during ctDNA screening phase\n   * Previous adjuvant CDK4\u002F6 inhibitor or PARP-inhibitor treatment is allowed provided it is completed\n   * Invasive multicentric \u002F multifocal disease is allowed provided that all the tested foci are ER+ HER2-. A sample from the highest-risk one, according to the investigator decision based on the size and grade, should be sent to Natera to build the patient ctDNA assay.\n   * Available tumour sample from resected or biopsied tissue, with a tumour content of ≥20% (30% preferred) either before or after macro dissection (if performed) and a cell viability of a minimum 100 cells.\n   * Core Needle Biopsies (CNB): recommended minimum of four (4) cores per block\n   * Fine Needle Aspirates (FNA) are not accepted\n   * The following sample types are acceptable:\n   * 6-10 unstained slides (charged and unbaked) of 10μm each (or 12-19 unstained slides at 5 μm each), PLUS one contiguous H\\&E slide. Minimum total tissue thickness must be 60μm OR\n   * FFPE tissue block with 25mm2 minimum surface area\n   * Written informed consent must be given according to ICH\u002FGCP, and national\u002Flocal regulations.\n\n   Main exclusion criteria:\n   * Suspected recurrent disease or known conflicts with the inclusion and exclusion criteria for the randomised trial\n   * Prior treatment with any SERD or investigational ER antagonist\n   * Previous history of invasive breast cancer\n   * Previous history of any other malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.\n   * Previous history of bone marrow and\u002For organ transplant\n   * Bilateral invasive breast cancer\n   * Participation in another clinical study, with the exception of the SURVIVE study and observational (non-interventional) and non-drug intervention clinical studies. Note: patients participating in interventional studies may participate once they enter the follow-up period of the study\n   * Blood transfusion within 3 months prior to registration or during the screening.\n2. Randomised trial:\n\nMain inclusion criteria:\n\n* ctDNA positive according to the Signatera ctDNA assay (main study ctDNA test) or other ctDNA assay approved for diagnostic purposes.\n* Patients must meet the eligibility criteria for the screening phase, with the exception of the tissue sample requirements.\n* Patients must receive adjuvant ET at the time of the ctDNA positive test\n* Absence of locoregional and\u002For metastatic disease and\u002For new malignancy, as investigated by:\n* Mammogram (unilateral in case of mastectomy; not required in patients having undergone bilateral mastectomy) NOTE: if local investigator plans to use MRIs instead of mammograms during the study, MRI will have to be performed at baseline.\n* CT thorax and abdomen\u002Fpelvis with IV contrast. In case of any contra-indications (medical or regulatory): CT thorax without contrast + MRI abdomen\u002Fpelvis.\n* Technetium-99m bone scintigraphy\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1\n* Adequate organ function\n* Women of childbearing potential (WOCBP) must have a negative highly sensitive serum or urine pregnancy test within 7 days prior to randomisation.\n\nMain exclusion criteria:\n\n* Any unresolved toxic effect of prior therapies or surgical procedures of Grade ≥ 2 according to Common Terminology Criteria of Adverse Events (CTCAE) v5.0, with the exception of alopecia, peripheral neuropathy and other toxicities not considered a safety risk for the participant at investigator's discretion\n* Unable or unwilling to avoid over-the-counter medications, dietary\u002Fherbal supplements, and\u002For foods that are moderate\u002Fstrong inhibitors or inducers of CYP3A4 activity\n* Known difficulty in tolerating oral medications or conditions which would impair absorption of oral medications\n* Any of the following cardiovascular disorders within 3 months before enrolment:\n* myocardial infarction\n* stroke\n* severe\u002Funstable angina\n* symptomatic cardiac arrhythmia\n* prolonged QTcF ≥ Grade 3 (i.e., \\> 500 msec)\n* heart failure ≥ Class III as defined by the New York Heart Association (NYHA) guidelines\n* CTCAE version 5.0 grade 3 or 4 dyslipidemia at the time of screening, defined as cholesterol\\>400 mg\u002FdL or \\>10.34 mmol\u002FL and\u002For triglycerides\\>500 mg\u002FdL or \\>5.7 mmol\u002FL.\n* Child-Pugh Score greater than Class A\n* Uncontrolled significant active infections (≥ grade 3 according to CTCAE version 5), including active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency Virus (HIV)\n* Coagulopathy or any history of coagulopathy within the past 6 months, including history of deep vein thrombosis or pulmonary embolism","ALL","18 Years",{"count":20,"type":21},220,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is an international, multi-center, randomised, open label, superiority phase III trial of elacestrant vs standard endocrine therapy in patients with ER+\u002FHER2- breast cancer and ctDNA relapse.\n\nDuring the ctDNA screening phase, patients will be tested at different timepoints to detect the presence of ctDNA in their blood.\n\nPatients who are found to be ctDNA-positive and have no evidence of distant metastasis, will be randomised 1:1 between standard endocrine treatment (the same they were receiving when tested ctDNA positive) versus elacestrant, provided they meet all eligibility criteria. After completion of the protocol treatment period, treatment will be left at the discretion of the treating physician.",[27,28,29,30],"ER-positive Breast Cancer","HER2-negative Breast Cancer","Stage IIB Breast Cancer","Stage III Breast Cancer","RECRUITING","2026-05-13",{"date":34,"type":35},"2026-05-15","ACTUAL",{"date":37,"type":35},"2023-12-15",{"date":39,"type":21},"2035-11-01",{"name":41,"class":42},"European Organisation for Research and Treatment of Cancer - EORTC","NETWORK",109,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100480377","telehealth-resistance-exercise-intervention-to-preserve-dose-intensity-and-vitality-in-elder-breast-cancer-patients-100480377","NCT05535192","TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients","TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients (THRIVE-65)","THRIVE-65","Inclusion Criteria:\n\n* Women age \\>=65\n* Diagnosed with stage I-III invasive breast cancer\n* BMI between 18-50 kg\u002Fm2\n* Scheduled to begin at least 10 weeks of neoadjuvant or adjuvant cytotoxic chemotherapy for curative intent\n* If enrolled in clinical chemotherapy drug trial, considered eligible if regimen includes an anthracycline or a taxane, unless the trial alters the chemotherapy agents\u002Fdoses according to patient response (e.g.; I-SPY trials)\n* Self-reported ability to walk for 6 minutes and\u002For 2 blocks (with or without assistive device)\n* Ability to provide written informed consent.\n* Ability to understand, speak, and read English. This is because many of the study instruments used are not readily available in multiple languages. Additionally, site-based study staff, such as exercise physiologists, are not bilingual and not all sites have access to interpreters.\n\nExclusion Criteria:\n\n* Following a therapeutic diet for co-morbid disease where the THRIVE-65 diet would be contraindicated as assessed by the RD\n* Engaging in 2 or more sessions of strength training exercise per week over a period of at least 3 consecutive months over the past year\n* Engaging in aerobic activity at a level that includes competitive events (e.g., marathon, triathlon, running races) over the past year\n* Presence of medical conditions or medications that would prohibit participation in an exercise program\n* Current use of weight-loss medication\n* Documented history of alcohol or substance abuse within the past 12 months\n* History of dementia","FEMALE","65 Years",{"count":55,"type":21},270,[57],"NA","This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are receiving chemotherapy for breast cancer to receive all of their planned chemotherapy according to schedule and at the planned dose.",[60,30,61,62,63],"Breast Cancer","Breast Cancer Female","Stage I Breast Cancer","Stage II Breast Cancer",[60,30,63,62,65,66,67],"Exercise Intervention","Nutrition Intervention","Supportive Care","2026-04-21",{"date":70,"type":35},"2026-04-23",{"date":72,"type":35},"2023-03-20",{"date":74,"type":21},"2027-02-01",{"name":76,"class":77},"Dana-Farber Cancer Institute","OTHER",3,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100485016","improving-exercise-capacity-with-a-tailored-physical-activity-intervention-100485016","NCT05595577","Improving Exercise Capacity With a Tailored Physical Activity Intervention","Improving Exercise Capacity With a Tailored Physical Activity Intervention in Lymphoma and Breast Cancer Patients Undergoing Treatment","PALS","Inclusion Criteria:\n\nTo be considered eligible, participants must meet all of the following criteria:\n\n* Individuals aged 18- 85 years\n* Diagnosed with stage I-IV Hodgkin's or non-Hodgkin's lymphoma or stage I-III breast cancer\n* Expected to receive an anthracycline based chemotherapeutic regimen or other potentially cardiotoxic cancer therapies (e.g. chemotherapy regimens \\[anthracyclines, trastuzumab, rituximab\\]), immuno-therapies (immune checkpoint inhibitors \\[ICI's\\]) or radiation (within 8 weeks of completion of radiation).29-31\n* Ability to speak and understand English\n* Capacity to walk at least 2 city blocks (\\~.2 miles) on a flat surface\n* Expected survival beyond 6 months.\n* Must have an assistant that will help perform the home-based testing activities\n\nExclusion Criteria:\n\nIf the patient meets any of these criteria they are excluded from the study:\n\n* Uncontrolled hypertension (systolic blood pressure \\>190 mm Hg or diastolic blood pressure \\>100 mm Hg)\n* Recent history of alcohol or drug abuse, inflammatory conditions such as lupus or inflammatory bowel disease, or another medical condition that might compromise safety or successful completion (unless approved by the participant's physician and the Principal Investigator) NOTE: In the setting of active inflammation, participation will not be approved. If chronic disease is present and stable as judged by the participant's physician and the PI, participation will be approved.\n* Contraindications to MRI such as ferromagnetic cerebral aneurysm clips or other intracranial metal, pacemakers, defibrillators, functioning neurostimulator devices or other implanted electronic devices (unless approved by the participant's physician and the Principal Investigator)\n* Pregnant\n* Unstable angina\n* Contraindication for exercise training or testing\n* Inability to exercise on a treadmill or stationary cycle\n* Significant ventricular arrhythmias (\\>20 PVCs\u002Fmin due to gating difficulty)\n* Atrial fibrillation with uncontrolled ventricular response\n* Acute myocardial infarction within 28 days\n* Inability to provide informed consent","85 Years",{"count":89,"type":21},110,[57],"The purpose of this research is to test whether participating in either a physical activity intervention or a series of educational classes will help to preserve exercise capability, heart function, brain-based activities (like memory), and quality of life.\n\nParticipants will be randomized to 1 of 2 pathways:\n\n* First pathway consists of organized health workshops. These workshops are intended to provide information on topics such as proper nutrition, management of stress, sleep practices, and emphasis on a healthy lifestyle that may help the participants through cancer treatment. This pathway will also test whether stretching may help participants through cancer treatment.\n* Second pathway participants will take part in some unsupervised and some potentially supervised moderate activity sessions each week throughout participants' cancer treatment to take place either remotely or in person, depending on availability of facilities at the time visits are scheduled.",[93,94,95,96,62,63,30],"Non Hodgkin Lymphoma","Heart; Functional Disturbance","Hodgkin Lymphoma","Quality of Life",[98,99],"Exercise capability","Brain activity","2026-03-19",{"date":102,"type":35},"2026-03-20",{"date":104,"type":35},"2023-03-01",{"date":106,"type":21},"2026-08-31",{"name":108,"class":77},"Wake Forest University Health Sciences",2,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":121,"conditions":122,"keywords":130,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100596217","phase-4-a-study-of-revaree-plus-in-people-with-breast-cancer-100596217","NCT07042581","A Study of Revaree Plus in People With Breast Cancer","Evaluation of Revaree Plus in Women With Breast Cancer","Inclusion Criteria:\n\n* ≥18 years of age at the time of signing informed consent.\n* Stage 0-3 hormone-receptor positive breast cancer confirmed at MSKCC\n* Able to complete study questionnaires in English or Spanish\n* Breast cancer patients must have completed primary therapy (surgery, and\u002For chemotherapy, and\u002For radiation therapy) or currently on maintenance therapy\n* Currently on an aromatase inhibitor or tamoxifen or Selective Estrogen Receptor Modulators (SERM)\n* Currently have no clinical evidence of disease\n* Reporting being bothered by vaginal symptoms of estrogen deprivation (i.e., vaginal dryness, dyspareunia, or discomfort \\[pain with intercourse or examination\\])\n* A total score of 4 or greater in VAS\n* Without history of other cancers (excluding non-melanoma skin cancer)\n* Must sign an informed consent indicating that the participant understands the purpose of, and procedures required for the study and is willing to participate in the study\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Vaginal bleeding of unknown etiology within 12 months of study entry\n* Currently taking hormone replacement therapy \\[local or systemic\\] (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment)\n* Existing use of external estrogens or nonhormonal moisturizers (Patients must discontinue for 4 weeks in order to be eligible prior to study enrollment)\n* No known allergies to any ingredients in 10mg HLA suppository",{"count":118,"type":21},60,[120],"PHASE4","The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.",[60,123,62,63,30,124,125,126,127,128,129],"Stage 0 Breast Cancer","Stage 0 Breast Carcinoma","Stage II Breast Carcinoma","Stage III Breast Carcinoma","Hormone-receptor-positive Breast Cancer","Hormone Receptor Positive Breast Carcinoma","Hormone Receptor Positive Malignant Neoplasm of Breast",[60,123,62,63,30,131,132,133,134,135,136,137],"Stage 0 hormone receptor positive breast cancer","Stage I hormone receptor positive breast cancer","Stage II hormone receptor positive breast cancer","Stage III hormone receptor positive breast cancer","Revaree","24-374","Memorial Sloan Kettering Cancer Center","2026-02-04",{"date":140,"type":35},"2026-02-06",{"date":142,"type":35},"2025-06-20",{"date":144,"type":21},"2029-06-20",{"name":137,"class":77},7,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":167,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100578450","mindfulness-based-intervention-for-depressive-symptoms-sent-via-text-mindset-100578450","NCT06811454","Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET)","A Daily, Digital Mindfulness-Based Intervention for Depressive Symptoms After Serious Medical Illness","Inclusion Criteria:\n\n1. Self-reported mild to moderately-severe symptoms of depression (score 5-19 on PHQ-9).\n2. A diagnosis of stage 0-III breast, prostate, or colorectal cancer.\n3. Completion of primary cancer treatment within 2 years (excludes hormone therapy).\n4. An ability to provide informed consent.\n5. An ability to read and speak English.\n6. Access to a web-enabled device (phone, tablet, computer).\n\nExclusion Criteria:\n\n1. Self-reported minimal and severe depressive symptoms (\\\u003C4 and \\> 20 on PHQ-9).\n2. Self-reported suicidal ideation (\\>1 on item 9 PHQ-9).\n3. Another psychological, medical, or other condition\u002Fissue determined that necessitates priority treatment and\u002For that would interfere with participation (e.g., schizophrenia, borderline personality disorder)\n4. Current or recent substance abuse\u002Fdependence.\n5. Stage IV cancer diagnosis.\n6. A cancer recurrence actively requiring treatment.\n7. Self-reported active mindfulness practice.\n8. Prior participation in a formal mindfulness program (e.g., MBCT, Mindfulness-Based Stress Reduction Program, Mindfulness-Based Cancer Recovery",{"count":155,"type":21},76,[57],"The purpose of this study is to develop and test a new intervention to reduce depressive symptoms in post-treatment cancer participants.",[159,160,30,63,62,161,162,163,164,165,166],"Depression","Cancer","Stage III Prostate Cancer","Stage II Prostate Cancer","Stage I Prostate Cancer","Stage III Colorectal Cancer","Stage II Colorectal Cancer","Stage I Colorectal Cancer",[168],"Post treatment Depression","NOT_YET_RECRUITING","2026-01-22",{"date":172,"type":35},"2026-01-23",{"date":174,"type":21},"2026-08-03",{"date":176,"type":21},"2029-03-31",{"name":178,"class":77},"Case Comprehensive Cancer Center",1,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":187,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":179},"100617088","phase-2-18ffes-petct-for-the-detection-of-distant-metastasis-in-low-grade-er-positive-stage-iii-breast-cancer-100617088","NCT07314073","[18F]FES PET\u002FCT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer","A Phase 2, Open-label, Non-randomized, Single Center Study Evaluating 18F-Fluoroestradiol Positron Emission Tomography\u002FComputed Tomography for the Detection of Distant Metastases in Low-grade, Estrogen Receptor-positive Stage III Breast Cancer","Inclusion Criteria:\n\n1. Male or female patients aged ≥19 years, regardless of race\u002Fethnicity\n2. Patients newly diagnosed with invasive breast cancer within 90 days prior to screening, with documented histopathological confirmation.\n3. Patients diagnosed with histologically confirmed estrogen receptor-positive, histologic grade 1 or 2 primary breast cancer\n4. Patients with clinical stage IIIA-IIIC disease according to the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system\n5. Patients who have undergone, or are scheduled to undergo chest computed tomography (CT), abdominal CT, and bone scintigraphy within 90 days prior to screening before the 18F-FES PET\u002FCT scan\n6. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of ≤2\n\nExclusion Criteria:\n\n* The subject or the subject's legally authorized representative has not signed the informed consent form\n* Subjects who are currently receiving systemic therapy for breast cancer (e.g., neoadjuvant chemotherapy, hormonal therapy)\n* Subjects with a history of another invasive malignancy within the past 2 years (except for non-melanoma skin cancer)\n* Subjects diagnosed with distant metastases on chest CT, abdominal CT, or bone scintigraphy performed within 90 days prior to screening or before the 18F-FES PET\u002FCT scan\n* Subjects for whom neither biopsy nor ≥6 months of follow-up imaging has been performed for lesions suspicious for distant metastases\n* Pregnant or breastfeeding women. The following cases are considered not at risk of pregnancy: (1) physiologically postmenopausal (no menses for ≥2 years), (2) surgically sterile (history of bilateral oophorectomy or hysterectomy), (3) women of childbearing potential with a documented negative serum or urine pregnancy test within 24 hours prior to 18F-FES administration, and who agree to use effective contraception during the trial.\n* Subjects with serious and\u002For uncontrolled and\u002For unstable medical conditions (e.g., congestive heart failure, acute myocardial infarction, severe pulmonary disease, chronic kidney disease, or chronic liver disease)\n* Subjects who are relatives or students of the investigator, or otherwise in a dependent relationship with the investigator\n* Subjects who, in the judgment of the investigator, are unable to provide complete data for the clinical trial due to personal circumstances or other reasons","19 Years",{"count":189,"type":21},85,[191],"PHASE2","This study aims to evaluate the detection rate of distant metastases using \\[18F\\]FES PET\u002FCT in patients with low-grade, ER-positive stage III breast cancer.",[30],[195,196,197,198],"breast cancer","estrogen receptor","[18F]FES PET\u002FCT","distant metastasis","2025-12-23",{"date":201,"type":35},"2026-01-02",{"date":203,"type":35},"2025-12-24",{"date":205,"type":21},"2029-12-31",{"name":207,"class":77},"Asan Medical Center",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":217,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":232},"100405007","phase-2-trastuzumab-deruxtecan-alone-or-in-combination-with-anastrozole-for-the-treatment-of-early-stage-her2-low-hormone-receptor-positive-breast-cancer-100405007","NCT04553770","Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer","A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting","Inclusion Criteria:\n\n* Previously untreated operable invasive carcinoma of the breast greater than 2.0 cm (cT2) in size based on physical exam or imaging. Patients with clinical node negative disease or clinical node (cN1\u002FcN2) positive are allowed provided they are deemed to have operable disease at study entry\n* Participants with clinically involved lymph nodes should not have radiological evidence of distant disease per standard of care staging prior to patient informed consent form (PICF) signature\n* In the United States\n* Tumor is HER2-low by immunohistochemistry (IHC), defined as 1+ or 2+, confirmed by central testing (central testing results not required for enrollment, unless no local results available). If HER2 is 2+ by IHC, fluorescence in situ hybridization (FISH) must be performed (per standard of care) and the FISH result must be HER2 non-amplified per 2018 American Society of Clinical Oncology College of American Pathologists (ASCO CAP) guidelines\n* Tumor is HR positive (HR+) per ASCO CAP guidelines with known estrogen and progesterone receptor status, locally defined\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Normal cardiac function (left ventricular ejection fraction \\[LVEF\\] \\>= 50%) based on echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization\u002Fenrollment\n* Platelet count \\>= 100 000\u002Fmm\\^3 (Platelet transfusion is not allowed within 1 week prior to screening assessment) (within 14 days before randomization\u002Fenrollment)\n* Hemoglobin \\>= 9.0 g\u002FdL (red blood cell transfusion is not allowed within 1 week prior to screening assessment) (within 14 days before randomization\u002Fenrollment)\n* Absolute neutrophil count (ANC) \\>=1500\u002Fmm\\^3 (Granulocyte colony-stimulating factor (G-CSF) administration is not allowed within 1 week prior to screening assessment) (within 14 days before randomization\u002Fenrollment)\n* Creatinine clearance \\>= 30 mL\u002Fmin as calculated using the Cockcroft-Gault equation or serum creatinine =\\\u003C 1.5 x upper limit of normal (ULN) (within 14 days before randomization\u002Fenrollment)\n* Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =\\\u003C 3 x ULN (within 14 days before randomization\u002Fenrollment)\n* Total bilirubin =\\\u003C 1.5 x ULN (within 14 days of randomization\u002Fenrollment). Participants with Gilbert's syndrome with a total bilirubin =\\\u003C 2.0 times ULN and direct bilirubin within normal limits are permitted\n* Serum albumin \\>= 2.5 g\u002FdL (within 14 days before randomization\u002Fenrollment)\n* International normalized ratio (INR)\u002Fprothrombin time (PT) and activated partial thromboplastin time (aPTT) =\\\u003C 1.5 x ULN (within 14 days before randomization\u002Fenrollment)\n* Has adequate treatment washout period before randomization\u002Fenrollment, defined as:\n\n  * Major surgery \\>= 4 weeks\n  * Chloroquine\u002Fhydroxychloroquine \\> 14 days\n* Negative pregnancy test (serum) for women of child bearing potential (CBP):\n\n  * Women are considered of CBP unless: they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment she is considered not of CBP\n* Male and female participants of reproductive\u002Fchildbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug. Highly effective contraception methods include:\n\n  * Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\n  * Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least 6 weeks before taking trial treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment\n  * Male partner sterilization (at least 6 months prior to randomization). For female patients on the trial the vasectomized male partner should be the sole partner for that patient. If vasectomy of the male partner is the highly effective method of contraception chosen, the success of the vasectomy should be medically confirmed according to local practice\n  * Placement of an intrauterine device (IUD)\n* Male participants must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study drug administration. Preservation of sperm should be considered prior to enrollment in this study\n* Female participants must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration\n* Estradiol level must be in post-menopausal range per local lab interpretation prior to baseline biopsy\n\n  * Postmenopausal status is defined as:\n\n    * Patient underwent bilateral oophorectomy, or\n    * Age \\>= 60 years, or\n    * Age \\\u003C 60 years and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifene or ovarian suppression) and follicle-stimulating hormone (FSH) and plasma estradiol are in the postmenopausal ranges per local normal ranges\n  * Note: for women with therapy-induced amenorrhea, serial measurements of FSH and\u002For estradiol per local clinical guidelines are required for determination of postmenopausal status. All women who do not meet the criteria for postmenopausal status are considered premenopausal for the purpose of this trial\n* Pre- or peri-menopausal and amenable to being treated with ovarian function suppression drugs (goserelin, leuprolide, or triptorelin) per standard of care. Patients must have started treatment with ovarian function suppression at least 28 days prior to first dose of study treatment\n\nExclusion Criteria:\n\n* Recurrent or metastatic breast cancer\n* Bilateral breast cancer (multifocal or multicentric breast cancer is allowed provided that all biopsied lesions are HER2 1+ or 2+, not FISH amplified and are HR positive per ASCO guidelines)\n* Inflammatory breast cancer\n* Prior systemic therapy for invasive cancer\n\n  * Prior tamoxifen for history of ductal breast carcinoma in situ (DCIS) allowed, but no prior aromatase inhibitor, no prior chemotherapy and no prior HER2-targeted therapy\n* Prior ipsilateral chest wall radiation\n* Major surgery \\\u003C 4 weeks prior to enrollment\n* Medical history of myocardial infarction within 6 months before randomization\u002Fenrollment, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV), troponin levels consistent with myocardial infarction as defined according to the manufacturer 28 days prior to randomization\n* Unable to swallow oral medications\n* Is pregnant or lactating, or planning to become pregnant\n* Corrected QT interval prolongation to \\> 470 ms (females) or \\> 450 ms (males) based on average of the screening triplicate 12-lead electrocardiogram\n* Known hypercoaguable disorder requiring use of anticoagulant\n* Significant gastrointestinal disorders limiting absorption or tolerance of oral medications (for example, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea)\n* History of (non-infectious) interstitial lung disease (ILD)\u002Fpneumonitis that required steroids, has current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening\n* Has multiple primary malignancies within 3 years, except:\n\n  * Adequately resected non-melanoma skin cancer\n  * Curatively treated non breast in-situ disease, and other solid non-breast tumors curatively treated are allowed if \\> 3 years from diagnosis and no evidence of recurrence in that time\n  * Prior history of DCIS is allowed as long as patient has not received an aromatase inhibitor, has not received ipsilateral breast\u002Fchest radiation\n  * Prior history of contralateral invasive breast cancer (diagnosed by biopsy \\> 2 years prior to current diagnosis) is allowed provided patient has not received prior aromatase inhibitor, CDK4\u002F6 inhibitor (CDK4\u002F6i), HER2-targeted therapy or chemotherapy and has not experienced any recurrence and has no evidence of recurrence (based on standard clinical evaluation)\n* Other concurrent anti-cancer therapy. Note: ovarian function suppression drugs (goserelin, leuprolide, or triptorelin) and\u002For bone modifying agents (bisphosphonates, denosumab) do not count as anti-cancer therapy for this criteria. If taking bisphosphonates or denosumab, must have been on these agents prior to signing consent\n* Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results\n* Has known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA). Subjects should be tested for HIV prior to randomization\u002Fenrollment if required by local regulations or Institutional Review Board (IRB)\u002Fethics committee (EC)\n* Have personal history within the last 12 months of any of the following conditions: syncope of cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest\n* Have received an autologous or allogeneic stem-cell transplant\n* Has active systemic bacterial infection (requiring intravenous \\[IV\\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \\[for example, hepatitis B surface antigen positive\\]). Screening is not required for enrollment\n* Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment must be stopped prior to first baseline biopsy\n* Has history of severe hypersensitivity reactions to other monoclonal antibodies and\u002For to either the drug substances or inactive ingredients in the drug product\n* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e. pulmonary emboli within three months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease \\[COPD\\], restrictive lung disease, pleural effusion etc.), and any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (i.e. rheumatoid arthritis, Sjogren's, sarcoidosis etc.), or prior pneumonectomy\n* Life expectancy \\\u003C 3 months",{"count":216,"type":21},88,[191],"This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing the growth of tumors that need estrogen to grow. This study is evaluating how effective trastuzumab deruxtecan is at treating hormone receptor positive cancer cells that have low levels of HER2 expressed on them when given alone or in combination with anastrozole.",[220,128,221,63,222,29,30],"Early-stage Breast Cancer","Invasive Breast Cancer","Stage IIA Breast Cancer","2025-11-06",{"date":225,"type":35},"2025-11-10",{"date":227,"type":35},"2020-10-09",{"date":229,"type":21},"2026-12-31",{"name":231,"class":77},"Jonsson Comprehensive Cancer Center",9,{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":243,"phases":4,"briefSummary":244,"conditions":245,"keywords":248,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":78},"100522784","predicting-breast-cancer-response-to-neoadjuvant-therapy-by-ctdna-assessment-100522784","NCT06087120","Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment","Investigate the Prognostic and Predictive Value of Circulating Tumor DNA (ctDNA) During Neoadjuvant Chemotherapy for Breast Cancer.","BRAVA","Inclusion Criteria:\n\n* Female,18 years old and older,\n* Are diagnosed with stage II-III HER2+\u002FTriple Negative breast cancer and indicated for neoadjuvant chemotherapy,\n* FFPE sample is available at the time of diagnosis and operation,\n* Are voluntary to participate in the study.\n\nExclusion Criteria:\n\n* Recurrent breast cancer,\n* Other cancer metastasis to the breast,\n* Have been or are being treated for cancer,\n* Patients did not agree to participate in the studies.",{"count":242,"type":21},125,"OBSERVATIONAL","This is a prospective and observational study, aiming to determine the detection rate and change of CtDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.\n\n* Determine the rate of ctDNA positivity at the time before treatment,\n* Determine the rate of ctDNA positivity at the time during treatment,\n* Determine the rate of ctDNA positivity at the time after neoadjuvant therapy, whether there is a change in ctDNA expression of the study population during treatment.\n\nAnd aiming to investigate the relationship between ctDNA expression and MRI imaging with pCR response in neo-adjuvant therapy:\n\n* Correlation between ctDNA detection and pCR response. Determine the percentage of Positive Prediction Value - PPV, Negative Prediction Value - NPV of ctDNA,\n* Correlation between MRI imaging and pCR response. Determination of PPV, NPV of MRI\n* Combination of ctDNA detection and MRI imaging in the prognosis of pCR. Determination of PPV, NPV ratio of ctDNA combined with MRI.",[61,63,30,246,247],"HER2-positive Breast Cancer","Triple Negative Breast Cancer",[249,250,251,252],"Liquid Biopsy","Circulating Tumour DNA","Vietnam","Indonesia","2025-09-18",{"date":255,"type":35},"2025-09-23",{"date":257,"type":35},"2023-09-16",{"date":259,"type":21},"2025-12-31",{"name":261,"class":262},"Gene Solutions","INDUSTRY",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":179},"100600255","a-study-of-disappearing-markers-for-daily-radiation-treatment-delivery-for-breast-cancer-patients-100600255","NCT07095114","A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.","A Phase I\u002FII Study of Disappearing Markers for Daily Radiation Treatment Delivery","Inclusion Criteria:\n\n* Participant must have histologically or cytologically confirmed stage 0 ductal carcinoma in situ (DCIS), I, II or III breast cancer and be planning to undergo radiation therapy (RT) after surgery\n* Participants must be 18 years of age or older\n* Participant must be able to understand a written informed consent document and be willing to sign it\n* Participant must be assigned female at birth\n* Participant must have a Karnofsky performance score of greater than or equal to 70%\n* Women of child bearing potential must agree to avoid becoming pregnant through defined periods during the course of RT and must meet one of the following:\n\n  * Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy\n  * Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation\n  * Agree to practice true abstinence from sexual intercourse\n  * Not in a sexual relationship in which the may become pregnant (i.e., same-sex relationship)\n  * If they are childbearing potential, agree to use at least one highly effective and at least one additional method of contraception.\n* For the first six participants only: Participant must have a Fitzpatrick Skin Tone Scale of 5 or 6\n\nExclusion Criteria:\n\n* Participants who have received prior radiation treatment to the affected breast.\n* Participants with a history of allergic reaction or hypersensitivity attributed to any tattoo ink\n* Participants with active chronic skin diseases such as psoriasis. Participants with inactive or controlled skin diseases are eligible for this study\n* Participants that are pregnant or breastfeeding. If a participant wishes to participate in this study, breastfeeding should be discontinued\n* Participants with a BMI greater than 44.5 as calculated within six months prior to the starting of the study. If there are multiple BMI measurements available in the chart, the most recent will be used to determine eligibility.",{"count":271,"type":21},30,[57],"The goal of this clinical trial is to learn if tattoos applied with Magic Ink is as safe as commercially available standard tattoo ink for the purpose of radiation in women with breast cancer undergoing radiation treatment. The main questions are:\n\n* Is the Magic Ink as safe as standard tattoo ink\n* Does Magic Ink continue to function and remain visible for radiation therapists during the treatment Participants will be consented and given a skin assessment. Once enrolled participants will be administered the Magic Ink tattoo instead of the standard tattoo ink in preparation for their radiation treatment. Participants will also complete a survey regarding body image. Skin assessment will occur again after the first week of radiation and at 3 months later. Throughout the radiation therapy the medical physicist will complete surveys about ease of set-up of the equipment.",[275,62,63,30],"Ductal Carcinoma in Situ","2025-09-12",{"date":253,"type":35},{"date":279,"type":35},"2025-08-18",{"date":281,"type":21},"2026-08-08",{"name":283,"class":77},"Barbara Ann Karmanos Cancer Institute",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":293,"briefSummary":294,"conditions":295,"keywords":298,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":4},"100602874","phase-2-shr-a1811-for-her2-positive-breast-cancer-with-suboptimal-neoadjuvant-response-100602874","NCT07129187","SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response","An Open-label, Single-arm, Multicenter Study of SHR-A1811 as Neoadjuvant Therapy in HER2-positive Breast Cancer Patients With Suboptimal Neoadjuvant Response","Inclusion Criteria:\n\n* 1.Female patients with newly diagnosed breast cancer aged 18 to 70 years old;\n* 2.Early or locally advanced HER2-positive invasive breast cancer;\n* 3.Known hormone receptor status;\n* 4.ECOG score of 0-1;\n* 5.Patients who were determined by the researchers to have poor therapeutic effect after 4 cycles of neoadjuvant therapy;\n* 6.Organ function levels must meet the following requirements:\n* 7.Women of childbearing age must undergo a serum pregnancy test within 7 days before enrollment, with a negative result, and be willing to use a medically approved highly effective contraceptive method during the study and within 3 months after the last administration of the study drug.\n* 8.The subjects voluntarily participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Patients with metastatic or bilateral breast cancer, or inflammatory breast cancer\n* 2\\. Patients with grade 3 or higher thrombocytopenia during previous treatment, or grade 3 or higher nausea and vomiting despite primary prevention\n* 3\\. History of other malignant tumors (except cured carcinoma in situ of the cervix, basal cell carcinoma, etc.) and related treatment history\n* 4\\. Patients who received major non-breast cancer surgery within 4 weeks before enrollment and have not recovered (except biopsy and PICC)\n* 5\\. Autoimmune diseases (except special cases such as hypothyroidism and stable type 1 diabetes)\n* 6\\. Interstitial lung disease, non-infectious pneumonia, uncontrolled systemic diseases\n* 7\\. History of or planned administration of live attenuated vaccines within 28 days\n* 8\\. HIV infection, active hepatitis (hepatitis B, hepatitis C, etc.), autoimmune hepatitis\n* 9\\. Severe infection within 4 weeks, CTCAE grade ≥ 2 active infection within 2 weeks (except neoplastic fever), or evidence of active tuberculosis within 1 year\n* 10\\. History of allogeneic bone marrow or solid organ transplantation\n* 11\\. Peripheral neuropathy of grade ≥ 2\n* 12\\. Severe heart diseases\n* 13\\. Receipt of systemic immunostimulant therapy within 4 weeks\n* 14\\. Receipt of systemic immunosuppressant therapy within 2 weeks (except local or physiological dose of hormones)\n* 15\\. Allergy to study drugs\u002Fexcipients, or history of severe allergic reaction to other monoclonal antibodies\n* 16\\. Pregnant or lactating women; fertile women with positive pregnancy test or unwilling to take effective contraception throughout the trial\n* 17\\. History of neurological\u002Fpsychiatric disorders , or history of substance abuse, alcoholism, or drug addiction\n* 18\\. Other circumstances deemed unsuitable for enrollment by the researcher","70 Years",{"count":271,"type":21},[191],"This is an open-label, single-arm, multicenter clinical study to evaluate the efficacy and safety of SHR-A1811 in early or locally advanced HER2-positive breast cancer patients with suboptimal response to neoadjuvant regimen. Patients who were determined by the researchers to have poor therapeutic effect will switch to SHR-A1811.",[296,297,63,30],"Early Breast Cancer","HER2 + Breast Cancer",[299,300,301,302],"neoadjuvant therapy","antibody drug conjugate","SHR-A1811","suboptimal response","2025-08-20",{"date":305,"type":35},"2025-08-26",{"date":307,"type":21},"2025-10",{"date":309,"type":21},"2030-10",{"name":311,"class":77},"Chuan Wang",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":22,"phases":322,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":340},"100587296","phase-3-postoperative-radiotherapy-in-breast-cancer--concurrent-or-sequential-with-chemotherapy-100587296","NCT06926543","Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy","Phase III Randomized Controlled Trial of Sequential Chemotherapy and Radiotherapy Versus Concurrent Chemoradiotherapy in Adjuvant Treatment of Breast Cancer (CONCERT)","CONCERT","Inclusion Criteria:\n\n1. Pathologically confirmed invasive breast cancer\n2. Stage IIB-III invasive breast cancer (AJCC 8th edition)\n3. Patients planned for adjuvant chemotherapy and adjuvant radiotherapy\n4. Patients fit to receive adjuvant chemotherapy and radiotherapy\n5. Age \\> 18 years\n\nExclusion Criteria:\n\n1. Hypersensitivity to taxanes\n2. Patients receiving entire chemotherapy prior to surgery (neoadjuvant setting)\n3. Unable or unwilling for regular follow up\n4. Bilateral tumour needed RT to both sides\n5. Patients planned for RT to oligometastatic sites\n6. Unfavourable anatomical factors potentially leading to higher radiotherapy dose to heart and\u002For lungs (Exceeding the protocol specific mandatory dose constraints).\n7. Pregnant patient",{"count":321,"type":21},858,[24],"This clinical research aims to determine if concurrent chemotherapy and radiation therapy is more effective than sequential chemotherapy and radiation therapy for patients with stage IIB-III breast cancer. It seeks to answer the following key questions:\n\n1. When compared to sequential treatment, does concurrent chemoradiotherapy increase disease-free survival?\n2. What effects does concurrent treatment have on post-operative look, quality of life, and side effects including arm swelling (lymphoedema)?\n3. What are each treatment approach's financial costs?\n\nResearchers will compare the following to groups:\n\nArm A: Participants in the sequential treatment group will first undergo chemotherapy and then radiation.\n\nand Arm B: Participants in the concurrent treatment group will undergo radiation therapy while undergoing chemotherapy.\n\nParticipants are going to:\n\n1. Get the usual chemotherapy (taxanes and\u002For anthracyclines).\n2. Receive radiation therapy for three to four weeks.\n3. Have follow-up visits every 6months for 5years to check for cancer recurrence, side effects, and quality of life.",[221,30,29],[326,327,328,329,330],"Invasive breast cancer","Chemoradiation","Sequential","Concurrent","adjuvant therapy","2025-04-07",{"date":333,"type":35},"2025-04-13",{"date":335,"type":35},"2024-05-14",{"date":337,"type":21},"2031-05",{"name":339,"class":77},"Dr. Tabassum Wadasadawala",5]